Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cost of Revenue: 2015-2024

Historic Cost of Revenue for Insight Molecular Diagnostics (IMDX) over the last 10 years, with Dec 2024 value amounting to $3.9 million.

  • Insight Molecular Diagnostics' Cost of Revenue rose 32.89% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 58.06%. This contributed to the annual value of $3.9 million for FY2024, which is 41.11% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Cost of Revenue of $3.9 million as of FY2024, which was up 41.11% from $2.8 million recorded in FY2023.
  • In the past 5 years, Insight Molecular Diagnostics' Cost of Revenue ranged from a high of $6.5 million in FY2020 and a low of $697,000 during FY2021.
  • Moreover, its 3-year median value for Cost of Revenue was $2.8 million (2023), whereas its average is $2.6 million.
  • In the last 5 years, Insight Molecular Diagnostics' Cost of Revenue soared by 200.09% in 2020 and then tumbled by 89.27% in 2021.
  • Yearly analysis of 5 years shows Insight Molecular Diagnostics' Cost of Revenue stood at $6.5 million in 2020, then slumped by 89.27% to $697,000 in 2021, then spiked by 62.41% to $1.1 million in 2022, then soared by 146.91% to $2.8 million in 2023, then spiked by 41.11% to $3.9 million in 2024.